Suchergebnisse - "PD-L1"

L’índex de PD-L1 en cèl·lules supressores d’origen mieloide com a biomarcador de la resposta a la immunoteràpia anti-PD-1/ PD-L1 en pacients oncològics

Autoren: Salvia Cerdà, Roser

Thesis Advisors: Pétriz González, Jordi, Álvarez Pérez, Ignacio Gerardo

Quelle: TDX (Tesis Doctorals en Xarxa)

Schlagwörter: MDSCs, PD-L1, Immunoteràpia, Immunotherapy, Immunoterapia, Ciències de la Salut

Dateibeschreibung: application/pdf

Zugangs-URL: http://hdl.handle.net/10803/695090

Feasibility and outcome of genomics-guided treatment selection in advanced cancer: the MEGALiT explorative clinical trial

Autoren: Ny, Lars Fagman, Henrik Botling, Johan et al.

Quelle: Acta Oncologica. 64:742-750

Schlagwörter: precision cancer medicine, genomics, clinical trial, targeted drug, PD-L1 inhibitor

Dateibeschreibung: electronic

Zugangs-URL: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-564293
https://doi.org/10.2340/1651-226X.2025.43366

Expression of PD-L1, TIGIT, and CD155, and Human Papillomavirus Status in Patients with Advanced Penile Cancer

Autoren: Ulvskog, E. Kirrander, Peter Persson, Erik K. et al.

Quelle: European Urology Open Science. 79:102-110

Schlagwörter: CD155, Chemotherapy, Human papillomavirus, PD-L1, Penile cancer, Radiotherapy, TIGIT, Tumor microenvironment

Dateibeschreibung: print

Zugangs-URL: https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-122986
https://doi.org/10.1016/j.euros.2025.07.012

In situ detection of PD1–PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC

Autoren: Lindberg, Amanda Muhl, Lars Yu, Hui et al.

Quelle: Journal of Thoracic Oncology. 20(5):625-640

Schlagwörter: Immune checkpoint inhibitor (ICI), Programmed death-ligand 1 (PD-L1), Programmed cell death protein 1 (PD1), non-small cell lung cancer (NSCLC), Proximity ligation assay (PLA)

Dateibeschreibung: electronic

Zugangs-URL: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-546466
https://doi.org/10.1016/j.jtho.2024.12.026

Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer-a population-based cohort study in Sweden

Autoren: Wagenius, Gunnar Vikström, Anders Berglund, Anders et al.

Quelle: Acta Oncologica. 64:415-422

Schlagwörter: Combination therapy, immune checkpoint inhibitor, monotherapy, overall survival, PD-L1

Dateibeschreibung: electronic

Zugangs-URL: https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-213907
https://doi.org/10.2340/1651-226X.2025.42746

Induction of Tolerogenic Dendritic Cells by a Noncoding Oligonucleotide

Autoren: Kamal, Kahkashan Trumbo, James Richardsdotter-Andersson, Elina et al.

Quelle: European Journal of Immunology. 55(10)

Schlagwörter: dendritic cell, noncoding oligonucleotides, PD-L1, Tregs, tolerance

Dateibeschreibung: print

Zugangs-URL: https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-249031
https://doi.org/10.1002/eji.70081

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Autoren: Ladjevardi, Cecilia Olsson Skribek, Marcus Koliadi, Anthoula et al.

Quelle: Cancer Immunology and Immunotherapy. 74(1)

Schlagwörter: PD-1 inhibitors, PD-L1 inhibitors, Immune-related adverse events, Advanced cancer, Cohort study

Dateibeschreibung: electronic

Zugangs-URL: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-543848
https://doi.org/10.1007/s00262-024-03869-1

Tumor Heterogeneity Confounds Lymphocyte Metrics in Diagnostic Lung Cancer Biopsies

Autoren: Elfving, Hedvig Thurfjell, Viktoria Mattsson, Johanna Sofia Margareta et al.

Quelle: Archives of Pathology & Laboratory Medicine. 148(1):e18-e24

Schlagwörter: lung cancer, immunotherapy, checkpoint inhibitors, tumor microenvironment, prognosis, PD-L1, lymphocytes

Dateibeschreibung: electronic

Zugangs-URL: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-517148
https://doi.org/10.5858/arpa.2022-0327-oa

Estudio del perfil genómico y de expresión en carcinomas escamosos cutáneos intraepiteliales e invasivos

Autoren: García Díez, Irene

Thesis Advisors: Toll Abelló, Agustí, Hernández Muñoz, Inmaculada, Pujol Vallverdú, Ramón M.

Quelle: TDX (Tesis Doctorals en Xarxa)

Schlagwörter: Carcinoma escatós cutani, Carcinoma escamoso cutáneo, Cutaneous squamous cell carcinoma, Càncer de pell, Cancer de piel, Skin cancer, PD-L1, Ciències de la Salut

Dateibeschreibung: application/pdf

Zugangs-URL: http://hdl.handle.net/10803/671613

Molecular genetic markers of breast cancer: current advances in understanding the etiology, prognostic value, and therapeutic opportunities

Autoren: M. M. Omarov V. V. Trusova L. M. Agabekyan et al.

Quelle: Акушерство, гинекология и репродукция, Vol 0, Iss 0 (2020)

Schlagwörter: breast cancer gene, her2, human epidermal growth factor receptor 2, cell proliferation marker ki-67, Gynecology and obstetrics, til, molecular markers of tumor cells, bc, breast cancer, pd-l1, programmed cell death receptor ligand 1, tumor-infiltrating lymphocytes, brca, RG1-991

Zugangs-URL: https://doaj.org/article/a8c2cf51c416451db59fca6db1464eb9

Inverse Regulation of TLR4 and PD‐L1 Shapes the Inflammatory Tumor Microenvironment in Oral Squamous Cell Carcinomas

Autoren: Camila Alves Ferri Giuseppe Pannone Maria Carmela Pedicillo et al.

Quelle: Journal of Oral Pathology & Medicine. 54:676-686

Schlagwörter: oral squamous cell carcinoma, PD-L1, tumor infiltrating lymphocytes (TIL), tumor microenvironment, CD8, mortality, TLR4

Dateibeschreibung: application/pdf

Zugangs-URL: https://hdl.handle.net/10447/687194
https://hdl.handle.net/10447/687194
https://doi.org/10.1111/jop.70012

Complete remission in an elderly patient with non-small cell lung cancer and brain metastasis using immunotherapy plus chemotherapy: a clinical case

Autoren: A. Chehal A. ALakkad H. Alkaabi et al.

Quelle: Сеченовский вестник, Vol 16, Iss 2, Pp 52-60 (2025)

Schlagwörter: immune checkpoint inhibitors, pd-l1 expression, Medicine (General), R5-920, central nervous system metastasis, poorly differentiated adenocarcinoma, pulmonary adenocarcinoma, personalized treatment

Zugangs-URL: https://doaj.org/article/e2d1bd407c7343c38bb77f8636815a29

Immunohistochemical analysis of PD-L1, CD4, CD8, CD20, and PU.1 expression in a dedifferentiated chondrosarcoma: the clinical and prognostic value

Autoren: Olga V. Kovaleva Irena V. Boulytcheva Dmitrii V. Rogozhin et al.

Quelle: Alʹmanah Kliničeskoj Mediciny, Vol 53, Iss 2, Pp 62-70 (2025)

Schlagwörter: pd-l1, immune therapy, cd20, Medicine, dedifferentiated chondrosarcoma, prognosis, cd8, pu.1 expression, cd4

Zugangs-URL: https://doaj.org/article/ae690c76bea14551b8da6e806c2558aa

PD-L1 Clones and Their Relevance in Glioblastoma, IDH-Wildtype: A Comparative Analysis

Autoren: Michal Hendrych Frantisek Vana Marketa Hermanova et al.

Quelle: Bratislava Medical Journal

Schlagwörter: Immunotherapy, Glioblastoma, PD-L1, SP263, 22C3, Biomarker

Polymer-assisted PD-L1 degradation and targeted photodynamic therapy synergize to suppress immunodeficient tumors

Autoren: Changyong Guo Shipeng He Huaxing Shen et al.

Quelle: Acta Pharm Sin B
Acta Pharmaceutica Sinica B, Vol 15, Iss 7, Pp 3805-3818 (2025)

Schlagwörter: PD-L1, Original Article, Immunotherapy, Therapeutics. Pharmacology, RM1-950, Protein degradation, Polymer, Photodynamic therapy, Immunogenic cell death

Zugangs-URL: https://doaj.org/article/7e546d0da23145859b3fa6ee1e39e89f

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Autoren: Saadettin, Kilickap Ana, Baramidze Ahmet, Sezer et al.

Weitere Verfasser: Saadettin, Kilickap Ana, Baramidze Ahmet, Sezer et al.

Quelle: Journal of Thoracic Oncology. 20:941-954

Schlagwörter: PD-L1, Non-small cell lung cancer, Programmed cell death-ligand 1 inhibitor, Lung neoplasms, Cemiplimab

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40118215
https://hdl.handle.net/20.500.12831/26763
https://doi.org/10.1016/j.jtho.2025.03.033

Synthesis of combretastatin analogues with antineoplastic properties

Autoren: Conesa Milián, Laura

Weitere Verfasser: University/Department: Universitat Jaume I. Escola de Doctorat

Thesis Advisors: Carda Usó, Miguel, Falomir Ventura, Eva

Quelle: TDX (Tesis Doctorals en Xarxa)

Schlagwörter: cancer, aminocombretastatin, angiogenesis, VEGFR-2, VDAs, PD-L1, Ciències naturals, químiques, físiques i matemàtiques

Dateibeschreibung: application/pdf

Zugangs-URL: http://hdl.handle.net/10803/667097

Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions

Autoren: Stefania Kokkali Ana Dolcan Kjetil Boye et al.

Quelle: Acta Oncol
Acta Oncologica, Vol 64 (2025)
Acta oncologica, vol. 64, pp. 761-768

Schlagwörter: sarcoma, programmed death-1 (PD-1), immune checkpoint inhibitor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Original Article, immunotherapy, Humans, Immune Checkpoint Inhibitors/therapeutic use, Sarcoma/drug therapy, Sarcoma/mortality, Sarcoma/pathology, Sarcoma/immunology, Female, Male, Middle Aged, Retrospective Studies, Aged, Adult, Europe/epidemiology, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Aged, 80 and over, Protein Kinase Inhibitors/therapeutic use, Young Adult, Progression-Free Survival, programmed death-ligand 1 (PD-L1), RC254-282

Dateibeschreibung: application/pdf

Zugangs-URL: https://doaj.org/article/fccb151a124e48c49e1d36bedf587a94
https://serval.unil.ch/resource/serval:BIB_A3EBC3572F69.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_A3EBC3572F698
https://serval.unil.ch/notice/serval:BIB_A3EBC3572F69

Evaluation of PD-L1, TERT promoter mutations, and BRAFV600E mutation in poorly differentiated, differentiated high grade thyroid carcinoma and anaplastic carcinoma of the thyroid: our institutional experience

Autoren: Piermattei, Alessia Migliara, Giuseppe Feraco, Angela et al.

Quelle: Virchows Archiv. 487:605-618

Schlagwörter: PD-L1, Anaplastic thyroid carcinoma, Poorly differentiated carcinoma, Thyroid cancer

Programmed death-ligand 1 expression in surgically resected thymomas

Autoren: Luca Frasca Antonio Sarubbi Filippo Longo et al.

Quelle: Updates in Surgery. 77:1335-1343

Schlagwörter: PD-L1, Thymoma, Recurrence, Thymectomy, Thymic epithelial tumours

Dateibeschreibung: application/pdf

Zugangs-URL: https://hdl.handle.net/2108/423543
https://doi.org/10.1007/s13304-025-02242-w